Want to see GB:AVCT full AI Analyst Report?
AVCT Stock Chart & Stats
65.00 p
-0.10 p(-0.19%)
At close: 4:00 PM EST
65.00 p
-0.10 p(-0.19%)
Day’s Range― - ―
52-Week Range31.38 p - 92.00 p
Previous CloseN/A
Volume371.99K
Average Volume (3M)3.07M
Market Cap
£320.86M
Enterprise Value342.34M
Total Cash (Recent Filing)£16.86M
Total Debt (Recent Filing)£14.92M
Price to Earnings (P/E)―
Beta0.82
Next Earnings
Oct 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding471,330,500
10 Day Avg. Volume4,236,507
30 Day Avg. Volume3,069,625
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)93.68
Price to Sales (P/S)2052.69
P/FCF Ratio-9.35
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.07
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
On-time Clinical ExecutionDelivering first-in-human dosing on schedule demonstrates operational and trial execution capability. Reliable trial execution reduces timeline risk, strengthens credibility with potential partners and investors, and increases the likelihood of timely data-driven value inflection over the next 2–6 months.
Preclinical Differentiation Vs ADCsMechanistic advantages showing substantially higher tumor exposure and selectivity represent durable competitive differentiation. If translated clinically, this could improve efficacy/safety tradeoffs, enhance partner interest, and support stronger IP and licensing economics over medium-term development.
Fundraising And Focused R&D InvestmentRecent successful fundraises combined with a 31.5% R&D spend increase show management commitment to advancing prioritized programs. The capital allows execution of key clinical readouts and platform work in the near term, supporting durable progress toward value-inflecting milestones.
Bears Say
Eroding Balance Sheet And LeveragePersistent equity erosion and a smaller asset base reduce financial flexibility and raise dilution risk. With returns on equity negative and a thinner equity cushion, the company faces constrained options to self-fund development or withstand setbacks without dilutive financing or restrictive partner deals.
Limited Cash Runway / Cash BurnA runway measured in quarters forces near-term funding decisions that materially shape strategy. The need to secure financing or partner arrangements within the coming months increases execution risk, can lead to dilutive capital raises, and may compel prioritisation that delays other programs.
Dependence On Partnering For Pivotal DevelopmentRequiring a partner before initiating pivotal studies transfers critical development and commercial execution to third parties. This dependency lengthens timelines, reduces control over trial design and commercial capture, and makes long-term value realization contingent on successful deal-making.
Avacta Group plc News
AVCT FAQ
What was Avacta Group PLC’s price range in the past 12 months?
Avacta Group PLC lowest share price was 31.38 p and its highest was 92.00 p in the past 12 months.
What is Avacta Group PLC’s market cap?
Avacta Group PLC’s market cap is £320.86M.
When is Avacta Group PLC’s upcoming earnings report date?
Avacta Group PLC’s upcoming earnings report date is Oct 05, 2026 which is in 79 days.
How were Avacta Group PLC’s earnings last quarter?
Avacta Group PLC released its earnings results on May 19, 2026. The company reported -0.051 p earnings per share for the quarter, missing the consensus estimate of N/A by -0.051 p.
Is Avacta Group PLC overvalued?
According to Wall Street analysts Avacta Group PLC’s price is currently Overvalued.
Does Avacta Group PLC pay dividends?
Avacta Group PLC does not currently pay dividends.
What is Avacta Group PLC’s EPS estimate?
Avacta Group PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Avacta Group PLC have?
Avacta Group PLC has 471,330,500 shares outstanding.
What happened to Avacta Group PLC’s price movement after its last earnings report?
Avacta Group PLC reported an EPS of -0.051 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.959%.
Which hedge fund is a major shareholder of Avacta Group PLC?
Currently, no hedge funds are holding shares in GB:AVCT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Avacta Group plc Stock Smart Score
Company Description
Avacta Group PLC
Avacta Group Plc operates as a clinical-stage biopharmaceutical company, specializing in the development of cancer therapies and diagnostic solutions. These advancements are driven by its proprietary Affimer and pre|CISION technology platforms, with the company's activities spanning the United Kingdom, North America, South Korea, and broader regions of Asia and Europe. Functioning across distinct Diagnostics and Therapeutics segments, Avacta's diagnostic endeavors include crafting bespoke Affimer proteins for customer products, developing internal diagnostic assays such as the AffiDX SARS-CoV-2 rapid antigen test, and supplying Affimer reagents for integration into third-party offerings. Concurrently, its Therapeutics division is dedicated to pioneering novel cancer immunotherapies through the strategic combination of its proprietary technologies. The company maintains a comprehensive network of collaborations, notably including a research partnership focused on its pre|CISION technology, which utilizes a substrate highly sensitive to cleavage by fibroblast activation protein alpha. Further key alliances encompass a drug development collaboration with LG Chem Life Sciences; a strategic partnership with Tufts University School of Medicine to advance Affimer drug conjugate therapies; a licensing agreement with POINT Biopharma Inc. for the creation of tumor-activated radiopharmaceuticals; and a drug development partnership with AffyXell, aimed at developing engineered mesenchymal stem cells for autoimmune disease treatment. Avacta Group Plc was established in 2003 and is headquartered in Wetherby, United Kingdom.
Technical Analysis
Nuformix Plc
―
PureTech Health
―
Scancell Holdings
―
4basebio UK Societas
―
Arecor Therapeutics PLC
―